Literature DB >> 12170257

Molecular virology and immunology of HIV infection.

Javier Chinen1, William T Shearer.   

Abstract

Great progress has been made with respect to our understanding of the immunopathogenesis of AIDS and the infectious agent, HIV, that causes the disease. HIV, a human retrovirus with tropism for CD4(+) T cells and monocytes, induces a decrease of T-cell counts, T-cell dysfunction, and, ultimately, immunodeficiency. HIV also causes B-cell dysfunction characterized by polyclonal activation, hypergammaglobulinemia, and lack of specific antibody responses. Chemokine receptors-mainly CCR5 and CXCR4-have been found to be necessary for viral entry into the host cell, a step that can be inhibited by chemokine-related molecules that are ligands for those receptors. After HIV infection, a strong cellular immunity develops and partially controls viral replication. It can take several years for HIV infection to become clinically evident. Studies in long-term nonprogressors have shown the determinant roles of both helper and cytotoxic T cells in the control of HIV disease. Advances in HIV immunology research are currently being applied in the development of prophylactic and therapeutic vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12170257     DOI: 10.1067/mai.2002.126226

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  23 in total

Review 1.  Bivalent ligands targeting chemokine receptor dimerization: molecular design and functional studies.

Authors:  Christopher Kent Arnatt; Yan Zhang
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

2.  Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents.

Authors:  Xueping Zhang; Kendra M Haney; Amanda C Richardson; Eden Wilson; David A Gewirtz; Joy L Ware; Zendra E Zehner; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2010-06-08       Impact factor: 2.823

3.  Persistently high IgA serum levels are a marker of immunological or virological failure of combined antiretroviral therapy in children with perinatal HIV-1 infection.

Authors:  Elena Chiappini; Luisa Galli; Pier-Angelo Tovo; Clara Gabiano; Maurizio de Martino
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

4.  Hormonal contraception and HIV disease progression: a multicountry cohort analysis of the MTCT-Plus Initiative.

Authors:  Elizabeth M Stringer; Mark Giganti; Rosalind J Carter; Wafaa El-Sadr; Elaine J Abrams; Jeffrey Sa Stringer
Journal:  AIDS       Date:  2009-11       Impact factor: 4.177

5.  Inexpensive designer antigen for anti-HIV antibody detection with high sensitivity and specificity.

Authors:  Sheikh M Talha; Teppo Salminen; Deepti A Chugh; Sathyamangalam Swaminathan; Tero Soukka; Kim Pettersson; Navin Khanna
Journal:  Clin Vaccine Immunol       Date:  2010-01-20

6.  Impact of age on markers of HIV-1 disease.

Authors:  Vanessa Pirrone; David J Libon; Christian Sell; Chad A Lerner; Michael R Nonnemacher; Brian Wigdahl
Journal:  Future Virol       Date:  2013-01       Impact factor: 1.831

7.  Antiretroviral therapy corrects HIV-1-induced expansion of CD8+ CD45RA+ CD2-) CD11a(bright) activated T cells.

Authors:  Li Yin; Carina A Rodriguez; Wei Hou; Olivia Potter; Margaret J Caplan; Maureen M Goodenow; John W Sleasman
Journal:  J Allergy Clin Immunol       Date:  2008-06-09       Impact factor: 10.793

Review 8.  Hormonal contraception and HIV disease progression.

Authors:  Elizabeth Stringer; Erik Antonsen
Journal:  Clin Infect Dis       Date:  2008-10-01       Impact factor: 9.079

9.  Comparative docking study of anibamine as the first natural product CCR5 antagonist in CCR5 homology models.

Authors:  Guo Li; Kendra M Haney; Glen E Kellogg; Yan Zhang
Journal:  J Chem Inf Model       Date:  2009-01       Impact factor: 4.956

10.  Prevalence and predictors of kaposi sarcoma herpes virus seropositivity: a cross-sectional analysis of HIV-infected adults initiating ART in Johannesburg, South Africa.

Authors:  Mhairi Maskew; A Patrick Macphail; Denise Whitby; Matthias Egger; Carole L Wallis; Matthew P Fox
Journal:  Infect Agent Cancer       Date:  2011-11-17       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.